Unknown

Dataset Information

0

Inter-hospital variation in the utilization of diagnostics and their proportionality in the management of adult community-acquired pneumonia.


ABSTRACT: Background:Utilization of diagnostics and biomarkers are the second largest cost drivers in the management of patients hospitalized with community-acquired pneumonia (CAP). The present study aimed to systematically assess the inter-hospital variation in these cost drivers in relation to antibiotic use in CAP. Methods:Detailed resource utilization data from 300 patients who participated in a multicenter placebo-controlled trial investigating dexamethasone as adjunctive treatment for community-acquired pneumonia was grouped into 3 categories: clinical chemistry testing, radiological exams, and microbiological testing. Based on the identified top 5 items per category, average costs were calculated per category and per hospital. Antibiotic de-escalation at day 3 and secondary ICU admission were assessed as outcomes for proportionality of diagnostics use. Results:The mean costs for diagnostics varied between hospitals from 350 (SD 31) to 841 (SD 37) euro per patient (p?

SUBMITTER: Vestjens SMT 

PROVIDER: S-EPMC6305565 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inter-hospital variation in the utilization of diagnostics and their proportionality in the management of adult community-acquired pneumonia.

Vestjens Stefan M T SMT   Wittermans Esther E   Spoorenberg Simone M C SMC   Grutters Jan C JC   van Ruitenbeek Charlotte A CA   Voorn G Paul GP   Bos Willem Jan W WJW   van de Garde Ewoudt M W EMW  

Pneumonia (Nathan Qld.) 20181225


<h4>Background</h4>Utilization of diagnostics and biomarkers are the second largest cost drivers in the management of patients hospitalized with community-acquired pneumonia (CAP). The present study aimed to systematically assess the inter-hospital variation in these cost drivers in relation to antibiotic use in CAP.<h4>Methods</h4>Detailed resource utilization data from 300 patients who participated in a multicenter placebo-controlled trial investigating dexamethasone as adjunctive treatment fo  ...[more]

Similar Datasets

| S-EPMC4269521 | biostudies-literature
| S-EPMC7768600 | biostudies-literature
| S-EPMC9286256 | biostudies-literature
| S-EPMC4600341 | biostudies-other
| S-EPMC6859251 | biostudies-literature
| S-EPMC2869386 | biostudies-literature
| S-EPMC5922336 | biostudies-literature
| S-EPMC7173092 | biostudies-literature
| S-EPMC1718998 | biostudies-literature
| S-EPMC2981274 | biostudies-literature